U.S. Markets open in 6 hrs 44 mins
  • S&P Futures

    3,601.25
    -0.25 (-0.01%)
     
  • Dow Futures

    28,861.00
    +60.00 (+0.21%)
     
  • Nasdaq Futures

    10,993.50
    -42.00 (-0.38%)
     
  • Russell 2000 Futures

    1,674.30
    +4.50 (+0.27%)
     
  • Crude Oil

    81.62
    +2.13 (+2.68%)
     
  • Gold

    1,671.70
    -0.30 (-0.02%)
     
  • Silver

    19.33
    +0.30 (+1.55%)
     
  • EUR/USD

    0.9799
    -0.0002 (-0.0196%)
     
  • 10-Yr Bond

    3.8040
    0.0000 (0.00%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1174
    +0.0007 (+0.0670%)
     
  • USD/JPY

    145.0960
    +0.3670 (+0.2536%)
     
  • BTC-USD

    19,196.18
    -144.03 (-0.74%)
     
  • CMC Crypto 200

    436.08
    -7.35 (-1.66%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

Terns Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

·1 min read
Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.

FOSTER CITY, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 2:00 p.m. ET.

A live audio webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including an allosteric BCR-ABL inhibitor, a THR-β agonist, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com